

 SERVIZIO SANITARIO REGIONALE EMILIA-ROMAGNA Azienda Ospedaliero-Universitaria di Modena Policlinico Servizio Ricerca e Innovazione	CONFLITTO DI INTERESSI NELLA UNITÀ DI FASE I (CENTRALE-OPERATIVA) E NEL CLINICAL TRIAL QUALITY TEAM	SRI PS05 Rev. 0 / 2016 Pag 7/8
---	---	--

DICHIARAZIONE PUBBLICA SUL CONFLITTO DI INTERESSI (vs 0 del 08/01/2016)

Nome

ERICA

Cognome

VILLA

Qualifica

DIRETTORE UO GASTROENTEROLOGIA

Ente di appartenenza AOU PUCCHINICO DI MODENA - UO
GASTROENTEROLOGIA

Si prega di elencare di seguito ogni eventuale interesse nell'industria farmaceutica (se necessario utilizzare più moduli).

Impegno nell'industria farmaceutica nel corso degli ultimi cinque anni:

- Tutte le attività svolte (direttamente o indirettamente) per ditte farmaceutiche (o per loro conto, in questo caso specificare il proprio ruolo e le attività svolte e indicare il nome del prodotto e la natura del lavoro svolto), sia che tali attività abbiano comportato o meno remunerazione regolare o occasionale, in denaro oppure in natura, fra le quali:
 - Partecipazione al processo decisionale interno di una ditta farmaceutica (per es. partecipazione al consiglio di amministrazione, direzione esecutiva o non esecutiva);
- Appartenenza permanente o temporanea al personale di una ditta farmaceutica. Altre attività svolte all'interno di una ditta farmaceutica (per es. tirocinio) sono ugualmente soggette a dichiarazione;
- Lavoro di consulenza o di altro genere, appaltato da ditte farmaceutiche
Abbiamo GSK, MSD - Lavoro di consulenza,
moderazione, relatore per congressi

Interessi finanziari nel capitale di un'industria farmaceutica:

Nome dell'industria: NA

Tipo di azione:

Numero di

azioni:

Altri rapporti con l'industria farmaceutica:

- Ogni tipo di assistenza e sostegno ricevuto dall'industria durante i precedenti 5 anni, comprendente o meno i benefici pecuniari o materiali, diretti o indiretti del tipo:
 - Borse di studio o di ricerca istituite dall'industria

 SERVIZIO SANITARIO REGIONALE EMILIA-ROMAGNA Azienda Ospedaliero-Universitaria di Modena Policlinico Servizio Ricerca e Innovazione	CONFLITTO DI INTERESSI NELLA UNITÀ DI FASE I (CENTRALE-OPERATIVA) E NEL CLINICAL TRIAL QUALITY TEAM	SRI PS05 Rev. 0 / 2016 Pag 8/8
---	---	--

o Fellowship o sponsorizzazioni sovvenzionate dall'industria farmaceutica.

Abbiamo convenzioni economiche per studi clinici

Altri interessi o fatti che si ritiene debbano essere portati a conoscenza, ivi compresi elementi relativi ai componenti del proprio nucleo familiare (i componenti del nucleo familiare sono: il coniuge, il/la compagno/a e i figli a carico che vivono sotto lo stesso tetto dell'interessato (*non è necessario menzionare il nome di tali persone*)).

NA

Il sottoscritto dichiara di non detenere, a sua conoscenza, altri interessi diretti o indiretti nell'industria farmaceutica oltre a quelli menzionati.

Dichiara inoltre che si impegna a presentare una nuova dichiarazione pubblica di conflitto di interessi qualora dovessero risultare nuovi o ulteriori interessi, tali da dover essere portati a conoscenza.

Inoltre, il sottoscritto autorizza la pubblicazione della presente dichiarazione sul sito internet dell'Azienda Ospedaliero-Universitaria Policlinico di Modena nella sezione dedicata.

In fede

[Firma]

04/10/2015 Data

PERSONAL INFORMATION

Erica Villa Via del Pozzo 71, 41124 Modena (Italy) +390594225308  +39594222624  +393484040393 erica.villa@unimore.it

Sex Female | Date of birth 10/07/1951 | Nationality Italian

WORK EXPERIENCE

-
- | | |
|-----------------------|---|
| 10/06/2013–Present | Member Institutional Review Board
Arcispedale Santa Maria Nuova, Reggio Emilia (Italy) |
| 01/11/2010–Present | Chairman of Department of Medicine Azienda Ospedaliero-Universitaria Policlinico, Modena
Azienda ospedaliero-universitaria Policlinico di Modena
via del Pozzo 71, 41124 Modena (Italy)
Administration, organization and management of the Department |
| 01/11/2007–Present | Chairman of Post-Doc School in Gastroenterology
University of Modena & Reggio Emilia
Via dell'Università, 41124 Modena (Italy)
Administration, organization and management of the post-Doc training |
| 01/11/2003–Present | Chief of Gastroenterology Unit
Azienda ospedaliero-universitaria policlinico
via del Pozzo 71, 41124 Modena (Italy)
Administration, organization and management of the Gastroenterology and Endoscopy Unit |
| 01/11/2002–Present | Professor of Gastroenterology
University of Modena & Reggio Emilia
via dell'Università, 41124 Modena (Italy)
Teaching Gastroenterology in the Faculty of Medicine, in the Dental School, in the Dietitian School |
| 01/11/2002–Present | Chief of Research Lab
University of Modena & Reggio Emilia
via dell'Università, 41124 Modena (Italy)
Administration, organization and management of the Research Lab of the Gastro Unit |
| 01/11/1992–31/10/2002 | Associate Professor Gastroenterology
University of Modena & Reggio Emilia
via dell'Università, 41124 Modena (Italy)
Teaching and Research |
| 01/09/1981–30/10/1992 | Hospital Assistant
Azienda Policlinico
via del Pozzo 71, 41100 Modena (Italy) |

Care of patients; endoscopic duties

EDUCATION AND TRAINING

27/07/2013–Present	Honorary Transplant Hepatologist Italian Association for the Study of the Liver (AISF)	
01/06/1997–31/08/1997	Visiting Professor University of San Diego, San Diego (United States) Research on Colon carcinogenesis	
01/11/1979–30/10/1983	Post doc in Immunology University of Milan, Milan (Italy) Specialty Course	Post-doc
01/01/1978–01/06/1979	Fellowship of the Anna Villa Rusconi Foundation Liver Unit, King's College Hospital Denmark Hill, London (United Kingdom) Basic research in Hepatitis field	Ph.D
01/11/1975–30/10/1979	Post doc Gastroenterology University of Modena % Reggio Emilia via dell'Università, 41124 Modena (Italy) Specialty Course in Gastroenterology	Post Doc
01/11/1969–18/07/1975	Degree in Medicine University of Modena and Reggio Emilia Via dell'Università, 41124 Modena (Italy)	Graduation

PERSONAL SKILLS

Mother tongue(s) Italian

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C2	C2	C2	C2	C2
German	B1	B1	B1	B1	B2
French	B2	B2	A2	A2	A2

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user
Common European Framework of Reference for Languages

Communication skills Excellent interpersonal skills acquired thanks to the intensive care, counseling and teaching. Excellent ability to fit in multicultural environments developed during the services rendered abroad through scholarships at the Liver Unit, King's College Hospital - London and at the Department of Gastroenterology at the University of La Jolla, UCSD, USA

Organisational / managerial skills

Involved in more than 15 GCPs studied per year (including phase I and phase II trials).
Excellent and longstanding organizational skills acquired in the direction of the department of Medicine, the Gastro Unit and of the Laboratory of Molecular Hepatology. Longstanding teaching experience

Job-related skills

Direction of a molecular biology laboratory in which are brought forward research on hepatitis viruses, on liver carcinogenesis and intestinal carcinogenesis.

Digital competence

SELF-ASSESSMENT				
Information processing	Communication	Content creation	Safety	Problem solving
Independent user	Independent user	Independent user	Basic user	Basic user

Digital competences - Self-assessment grid

Excellent knowledge of Mac OSX and Windows operating systems. Excellent knowledge of programs preparing texts, data and databases such as Microsoft Office and iWork. Internet browsing fast and effective. Good knowledge of advanced SPSS and other statistical packages.

Other skills

Academic Editor of PLOS1; Reviewer for more than 15 scientific journals (among them Gastroenterology, Hepatology, Endocrinology, Annals of Internal Medicine, Journal of Hepatology, APT); Member of AISE, SIGE, EASL); intense activity in the field of organ transplants. Piano player

Driving licence

B

ADDITIONAL INFORMATION

Global impact factor: about 990
H index: 35, i10 Index: 73
Selected papers (2015-2000)
1. Barbier-Torres L, Beraza N, Fernandez-Tussy t al. Histone deacetylase promotes cholestatic liver injury in absence of prohibitin-1. Hepatology (in press (IF 11.0)
2. Turola E, Petta S, Vanni E et al. Ovarian Senescence Increases Liver Fibrosis in Humans and Zebrafish with Steatosis. Diseases Model and Mechanisms in press (IF 5.0)
3. Villa E, Critelli R, Lei B, et al. Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. GUT 20152. (IF 14.4)
4. Della Noce I, Carra S, Brusegan C, Critelli R, Frassine A, De Lorenzo C, Giordano A, Bellipanni G, Villa E, Cotelli F, Pistocchi A, Schepis F. The Coiled-Coil Domain Containing 80 (ccdc80) Gene Regulates gadd45b2 Expression in the Developing Somites of Zebrafish as a New Player of the Hedgehog Pathway. J CELL PHYSIOL 2015 Apr; 230: 821-30 (3.8)
5. Giannelli G, Villa E, Lahn M. Transforming Growth Factor beta (TGF-β) as a Therapeutic Target in Hepatocellular Carcinoma. Cancer Research 2014; doi: 10.1158/0008-5472 (IF 9.3).
6. Cammà C, Cabibbo G, Petta S, Enea M, Iavarone M, Grieco A, Gasbarrini A, Villa E, Zavaglia C, Bruno R, Colombo M, Craxi A; on behalf of the WEF and the SOFIA study groups. Cost/effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. Hepatology. 2013;doi:10.1002/hep.26221 (IF 11.0)
7. Dituri F, Serio G, Filannino D, Mascolo A, Sacco R, Villa E, Giannelli G Circulating TGF-β1-related biomarkers in patients with hepatocellular carcinoma and their association with HCC staging scores. CANCER LETT 2014 Oct; 353: 264-71 (IF 5.0)
8. Barbier-Torres L, Delgado TC, García-Rodríguez JL, et al. Stabilization of LKB1 and Akt by

- neddylation regulates energy metabolism in liver cancer. *Oncotarget* 6, 2509, 2015 (IF 6.6)
9. Burra P, Martin ED, Gitto S, Villa E. Influence of age and gender before and after liver. *Liver Transpl*. 2013;19:122-34
10. Villa E, Vukotic R, Camm C, Petta S, Di Leo A, Gitto S, Turola E, Karampatou A, Losi L, Bernabucci V, Cenci A, Tagliavini S, Baraldi E, De Maria N, Gelmini R, Bertolini E, Rendina M, Francavilla A. Reproductive status is associated with the severity of fibrosis in women with hepatitis C. *PLoS One*. 2012;7:doi: 10.1371/journal.pone.0044624
11. Villa E, Cammà C, Marietta M, et al. Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients With Advanced Cirrhosis. *Gastroenterology*. 2012 Jul 20. [Epub ahead of print]
12. Villa E, De Maria N. Anticoagulation in cirrhosis. *Liver Int*. 2012;32(6):878-9. doi: 10.1111/j.1478-3231.2012.02825.x.
13. Villa E., Calogero Cammà, Alfredo Di Leo, et al. PEGIFN-A_{2B} plus ribavirin is more effective than PEGIFN-A_{2A} plus ribavirin in menopausal women with chronic hepatitis C. *Journal of viral hepatitis* 2012 *J Viral Hepat*. 2012;19:640-649. doi: 10.1111/j.1365-2893.2012.01593.x. Epub 2012 Mar 15.
14. Gitto S, Karampatou A, Andreone P, Villa E. Menopause, and not age, is a critical factor associated with a worse response to antiviral therapy in women affected by chronic hepatitis C. *Int J Infect Dis*. 2011 Dec 29. [Epub ahead of print]
15. Cariani E, Critelli R, Rota C, Luongo M, Trenti T, Villa E. Interleukin 28B genotype determination using DNA from different sources: A simple and reliable tool for the epidemiological and clinical characterization of hepatitis C. *J Virol Methods*. 2011;178:235-8.
16. Cariani E, Villa E, Rota C, Critelli R, Trenti T. Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymorphisms in hepatitis C virus (HCV) infection. *Clin Chem Lab Med*. 2011;49:1247-56.
17. Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, Cammà C, Colombo M; On behalf of the SOFIA (SOraFenib Italian Assessment) study group. Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy. *Hepatology*. 2011;54:2055-2063.
18. Villa E, Karampatou A, Cammà C, et al. Early Menopause Is Associated With Lack of Response to Antiviral Therapy in Women With Chronic Hepatitis C. *Gastroenterology*. 2011; 140:818-29
19. Villa E, Fattovich G, Mauro A, Pasino M. Natural history of chronic HBV infection: special emphasis on the prognostic implications of the inactive carrier state versus chronic hepatitis. *Dig Liver Dis*. 2011;43 Suppl 1:S8-14.
20. Villa E, Fattovich G. No inflammation? No cancer! Clear HBV early and live happily. *J Hepatol*. 2010; 52: 768-70.
21. Antonelli A, Ferri C, Ferrari SM, Villa E, Menichetti F, Fallahi P. Interleukin-1 β , C-x-C motif ligand 10, and interferon-gamma serum levels in mixed cryoglobulinemia with or without autoimmune thyroiditis. *J Interferon Cytokine Res*. 2010;30:835-42
22. Bianchini M, Cavina M, Boarino V, Begliomini B, De Maria N, Villa E. Massive GI bleeding due to accidental ASA inhalation. *Platelets*. 2010; 21:67-9.
23. Villa E. Androgen receptor alterations in hepatocarcinogenesis. *Dig Liv Dis*. 2009;41:632-3.
24. Morisco F, Stroffolini T, Medda E, Amoroso DC, Almasio PL, Villa E, Zuin M, Paris B, Stanzione M, Caporaso N & NADIR StudyGroup. Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study. *J Viral Hepat*. 2010; 17: 427-34.
25. Villa E, Lei B, Taliani G, Graziosi A, Critelli R, Luongo M, Gennari W, Bianchini M, Ferretti I. Pretreatment with pegylated interferon prevents emergence of lamivudine mutants in lamivudine-naïve patients: a pilot study. *Antivir Ther*. 2009;14:1081-7.
26. Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamin S, Moreno-Otero R, Canilho F, Schmidt W, Berg T, McGarity T, Heathcote EJ, Gonzales F, Diago M, Craxi A, Silva M, Bedossa P, Mukhopadhyay P, Griffel L, Burroughs M, Brass C, Albrecht J; Epic Study Group. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. *Gastroenterology*. 2009;136:1618-28.
27. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxi A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trivelpo C, Villa E, Will H, Zanetti AR, Zoulim F. Statements from the Taormina expert meeting on occult hepatitis B virus infection. *J Hepatol*. 2008;49:652-7.

28. Burra P, Tomat S, Villa E, Gasbarrini A, Costa AN, Conconi MT, Forbes SJ, Farinati F, Cozzi E, Alison MR, Russo FP; Italian Association for the Study of the Liver (AISF). Experimental hepatology applied to stem cells. *Dig Liver Dis.* 2008;40:54-61.
29. Villa E. Role of estrogen in liver cancer. *Womens Health (Lond Engl).* 2008;4:41-50.
30. Giradis M, Marietta M, Busani S, Codeluppi M, Villa E, Pasetto A. Rectal amputation sparing by haemostatic therapy with recombinant factor VIIa in a patient with cytomegalovirus-related colitis. *Thromb Haemost.* 2006;95:579-80.
31. Di Benedetto F, Lauro A, Masetti M, Cautero N, Quintini C, Dazzi A, De Ruvo N, Uso TD, Begliomini B, Siniscalchi A, Bagni A, Codeluppi M, Ramacciato G, Villa E, Pinna AD. Outcomes after adult isolated small bowel transplantation: experience from a single European centre. *Dig Liver Dis.* 2005;37:240-6.
32. Manno M, Cammà C, Schepis F, Bassi F, Gelmini R, Giannini F, Miselli F, Grottola A, Ferretti I, Vecchi C, De Palma M, Villa E. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. *Gastroenterology.* 2004;127:756-63.
32. Pollicino T, Squadrito G, Cerenza G, Cacciola I, Raffa G, Craxi A, Farinati F, Missale G, Smedile A, Tiribelli C, Villa E, Raimondo G. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. *Gastroenterology.* 2004;126:102-10.
33. Klomp LW, Vargas JC, ... Villa E, ... Bull LB Characterization of mutations in ATP8B1 associated with hereditary cholestasis. *Hepatology* 2004; 40: 27-38.
34. Villa E, Colantoni A, Cammà C et al. Estrogen receptor classification for HCC: Comparison with clinical staging systems. *Journal Clinical Oncology* 21;441-446, 2003.
35. Chironna M, Grottola A, Villa E, Quarto M. Genetic analysis of HAV strains recovered from patients with acute hepatitis from Southern Italy. *J Med Virol.* 2003; 70:343-9.
36. Grottola A, Buttafoco P, Del Buono MG, ... Villa E. Pre-transplant preS2 and S proteins heterogeneity predisposes to HBV recurrence after liver transplant. *Liv Transpl.* 2002; 8: 443-448
37. Villa E, Grottola A, Colantoni A, De Maria N, Buttafoco P. Hepatocellular carcinoma: role of estrogen receptors in the liver. *Ann N Y Acad Sci.* 2002; 963: 37-45.
38. Colantoni A, Emanuele M, Kovacs E, Villa E, Van Thiel D Hepatic estrogen receptors and alcohol intake *Mol Cell Endocrinol.* 2002; 193: 101.
39. De Maria N, ... Villa E. Sex hormones & liver cancer. *Mol.Cel.End.* 2002, 193:59.
40. Villa E, Colantoni A, Grottola A, et al. Variant estrogen receptors and their role in liver disease. *Mol Cell Endocrinol.* 2002; 193: 65.
41. Lei B, ... Villa E. Phytoestrogens and liver disease. *Mol.Cel.End.* 2002; 193: 81- 83
42. Farinati Fabio, Cardin R... Villa E. Estrogens receptors and oxidative damage in the liver. *Mol.Cel.End* 2002; 193: 85-87.
43. Villa E, Boarino V, Grottola A, et al. Predominance of PreS1 mutated HBV in a patient following treatment with adefovir dipivoxil. *Liver Transplant.* 2002; 8: 443-448;
44. Villa E, I Ferretti, A Grottola, P Buttafoco et al. Hormonal therapy with Megestrol in inoperable hepatocellular carcinoma characterised by variant estrogen receptors: a prospective, randomised, controlled trial. *Br J Cancer* 2001; 84: 881-5.
45. Villa E, A Grottola, P Buttafoco, et al. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. *Am J Gastroenterol.* 2001; 96: 2973-7
46. Battezzati PM, M Zuin, A Crosignani, M Allocca, P Invernizzi, C Selmi, Villa E, M Podda. Ten year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. *Aliment Pharmacol Ther.* 2001; 15: 1427-34.
47. Lerose R., Molinari R, Rocchi E. Manenti F, Villa E. Prognostic features and survival of HCC in Italy: impact of stage of disease. *Eur J Cancer.* 2001; 37: 239-245.
48. Villa E, Ferretti I, Buttafoco P, Grottola A et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptor status in the tumor is the strongest prognostic factor for survival. *Hepatology.* 2000, 32; 233-238.

I HEREBY AUTHORIZE THE PROCESSING OF MY PERSONAL DATA PURSUANT TO ITALIAN LAW NO. 196/03 ON PRIVACY

Prof.ssa VILLA ERICA
 47020 - G. F. VILL. RUE 51150 H2935
 Azienda Ospedaliera Patologia di Modena
 Gastroenterologia

6.10.16